Toll Free: 1-888-928-9744

Acne Vulgaris Global Clinical Trials Review, H1, 2016

Published: Apr 15, 2016 | Pages: 303 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acne Vulgaris Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Acne Vulgaris Global Clinical Trials Review, H1, 2016" provides an overview of Acne Vulgaris clinical trials scenario. This report provides top line data relating to the clinical trials on Acne Vulgaris. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10 Top Five Countries Contributing to Clinical Trials in Europe 11 Top Countries Contributing to Clinical Trials in North America 12 Top Countries Contributing to Clinical Trials in Middle East and Africa 13 Top Five Countries Contributing to Clinical Trials in Central and South America 14 Clinical Trials by G7 Countries: Proportion of Acne Vulgaris to Dermatology Clinical Trials 15 Clinical Trials by Phase in G7 Countries 16 Clinical Trials in G7 Countries by Trial Status 17 Clinical Trials by E7 Countries: Proportion of Acne Vulgaris to Dermatology Clinical Trials 18 Clinical Trials by Phase in E7 Countries 19 Clinical Trials in E7 Countries by Trial Status 20 Clinical Trials by Phase 21 In Progress Trials by Phase 22 Clinical Trials by Trial Status 23 Clinical Trials by End Point Status 24 Subjects Recruited Over a Period of Time 25 Clinical Trials by Sponsor Type 26 Prominent Sponsors 27 Top Companies Participating in Acne Vulgaris Therapeutics Clinical Trials 28 Prominent Drugs 30 Latest Clinical Trials News on Acne Vulgaris 31 Mar 03, 2016: BioPharmX commences Phase 2 clinical study under U.S. FDA IND for BPX-01 31 Mar 01, 2016: Novan Phase 2b Results with SB204 to be Presented at American Academy of Dermatology 31 Feb 23, 2016: Novan Announces First Patient Dosed in Phase 3 Program for SB204 31 Feb 15, 2016: Visonac Data Were Presented at The Euro PDT Congress in Barcelona February 13th 32 Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne 32 Clinical Trial Profile Snapshots 34 Appendix 300 Abbreviations 300 Definitions 300 Research Methodology 301 Secondary Research 301 About GlobalData 302 Contact Us 302 Disclaimer 302 Source 303
List of Tables
Acne Vulgaris Therapeutics, Global, Clinical Trials by Region, 2016* 6 Acne Vulgaris Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8 Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Acne Vulgaris Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10 Acne Vulgaris Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11 Acne Vulgaris Therapeutics Clinical Trials, North America, Top Countries, 2016* 12 Acne Vulgaris Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13 Acne Vulgaris Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14 Proportion of Acne Vulgaris to Dermatology Clinical Trials, G7 Countries (%), 2016* 15 Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16 Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17 Proportion of Acne Vulgaris to Dermatology Clinical Trials, E7 Countries (%), 2016* 18 Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19 Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20 Acne Vulgaris Therapeutics, Global, Clinical Trials by Phase, 2016* 21 Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22 Acne Vulgaris Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23 Acne Vulgaris Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24 Acne Vulgaris Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25 Acne Vulgaris Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26 Acne Vulgaris Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27 Acne Vulgaris Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29 Acne Vulgaris Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30


List of Figures
Acne Vulgaris Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Acne Vulgaris Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Acne Vulgaris Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10 Acne Vulgaris Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11 Acne Vulgaris Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12 Acne Vulgaris Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13 Acne Vulgaris Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14 Proportion of Acne Vulgaris to Dermatology Clinical Trials, G7 Countries (%), 2016* 15 Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16 Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17 Proportion of Acne Vulgaris to Dermatology Clinical Trials, E7 Countries (%), 2016* 18 Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19 Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20 Acne Vulgaris Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21 Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22 Acne Vulgaris Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23 Acne Vulgaris Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24 Acne Vulgaris Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25 Acne Vulgaris Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26 Acne Vulgaris Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27 Acne Vulgaris Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28 Acne Vulgaris Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30 GlobalData Methodology 301

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealan

Read More...

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...

Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among ot

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify